Cerezyme
What Cerezyme is used for
Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: anaemia after exclusion of other causes, such as iron deficiency Thrombocytopenia Bone disease after exclusion of other causes such as Vitamin D deficiency hepatomegaly or splenomegaly
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Cerezyme
- Active substance
- imiglucerase
- Disease area
- Gaucher Disease
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AB02
- Marketing authorisation holder
- Sanofi B.V.
- Authorised in the EU since
- 1997
Official information
In the USA
Same active substance: Cerezyme
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Cerezyme used for?
Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: anaemia after exclusion of other causes, such as iron deficiency Thrombocytopenia Bone disease after exclusion of other causes such as Vitamin D deficiency hepatomegaly or splenomegaly
What is the active substance in Cerezyme?
Cerezyme contains imiglucerase.
Who makes Cerezyme?
The EU marketing authorisation holder is Sanofi B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU